Balyasny Asset Management
IBB icon

Balyasny Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Balyasny Asset Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,500
Closed -$1.47M – 3059
2025
Q1 		$1.47M Sell
11,500
-151,900
-93% -$20.6M ﹤0.01% 1841
2024
Q4 		$21.6M Buy
163,400
+13,400
+9% +$1.88M 0.03% 629
2024
Q3 		$21.8M Sell
150,000
-23,100
-13% -$3.34M 0.04% 597
2024
Q2 		$23.8M Buy
173,100
+6,900
+4% +$921K 0.04% 546
2024
Q1 		$22.8M Buy
166,200
+16,200
+11% +$2.21M 0.04% 564
2023
Q4 		$20.4M Hold
150,000
– – 0.04% 594
2023
Q3 		$18.3M Buy
+150,000
New +$19.1M 0.04% 602

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Balyasny Asset Management's IBB Position: Q1 2025 in Review

Balyasny Asset Management sold out of iShares Biotechnology ETF (IBB) in Q1 2025, closing a stake of 35,859 shares — an estimated $4.86M sold.

Balyasny Asset Management first reported a position in IBB in Q3 2021 and held it in 9 quarters. The position peaked at $20.8M in Q3 2021. 831 funds tracked by Wall St. Rank hold IBB as of Q1 2025.

  • Balyasny Asset Management reported no remaining iShares Biotechnology ETF position as of Q1 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 35,859 iShares Biotechnology ETF shares in Q1 2025, an estimated $4.86M.
  • Balyasny Asset Management first reported a position in iShares Biotechnology ETF in Q3 2021 and held it in 9 quarters.
  • Balyasny Asset Management's iShares Biotechnology ETF position peaked at $20.8M in Q3 2021.
  • 831 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2025.

Based on Balyasny Asset Management's 13F filing for Q1 2025, filed 15 May 2025.